Secretory Carcinoma of the Parotid Gland: First Case Reported in Brazil

Jónatas C de Freitas1, Rodrigo S Honório2, Liandra R de S Barbosa3*, Francieudo J Rolim1 and Luis AA Ferreira1

1Department of Surgery, Federal University of Ceará-UFC, Brazil
2Department of Pathology, Albert Sabin Children's Hospital, Brazil
3Department of Medicine, Federal University of Ceará, Brazil

Abstract

The Mammary Analogue Secretory Carcinoma or MASC was first described by Skálová et al. [2]. In most cases, it presents as a low-grade histological tumor, with a low degree of aggressiveness and a relatively benign course; however, it has the potential to undergo a high-grade malignant transformation. The MASC usually presents as a nodule or small mass in the region of the parotid gland, which is not associated with any other symptoms. Here were port the case of patient treated in at Head and Neck Surgery Service of the Medical School of Federal University of Ceará with a nodule in the parotid region for whom a parotidectomy was indicated. The histopathological examination showed the presence of a mammary analogue secretory carcinoma, the first case reported in Brazil, to the best of our knowledge. Due to the compromised margins and extensive perineural invasion, adjuvant radiotherapy was indicated. The patient is in good overall condition, with no evidence of disease after one year of treatment.

Introduction

The salivary gland secretory carcinoma was recently added to the WHO classification of neck and head tumors in its 4th edition in 2017 [1], a term covering the neoplasia first described by Skálová et al. [2] as the mammary analogue secretory carcinoma or MASC. It is a very rare tumor that mainly affects the parotid gland [3].

To date, more than 100 cases of MASC [4] have been described. It seems to have a higher incidence in men than in women and it usually has a low course; however, sometimes there may be locally advanced disease, with lymph node involvement [5]. This type of tumor is characterized by the great similarity in the presentation of its morphological and immunohistochemical characteristics with the also rare secretory carcinoma of the breast.

The aim of the present study is to report the case of a patient with a mammary analogue secretory carcinoma treated at the Head and Neck Surgery Service of the Walter Cantídio University Hospital, which, to the best of our knowledge is the first case reported in Brazil.

Case Presentation

A 44-year-old female patient, with no prior comorbidities, sought medical attention after observing a nodule growth in the left parotid region, measuring approximately 3 cm, without facial paralysis or other clinical manifestations. Ultrasonography revealed a solid intra-glandular superficial nodular lesion, and partial left parotidectomy was indicated. Fine-needle aspiration biopsy was not diagnostic.

The histopathological analysis result of the anatomical specimen was not conclusive, also showing extensive perineural invasion and surgical margin compromised by the neoplasia (Figures 1-3), suggesting a malignant neoplasia, raising the initial hypotheses of mucoepidermoid carcinoma, mammary analogue carcinoma, acinar cell carcinoma or adenocarcinomas with No Other Specification (NOS).

The immunohistochemical analysis result of the anatomical specimen was not conclusive, also showing extensive perineural invasion and surgical margin compromised by the neoplasia (Figures 1-3), suggesting a malignant neoplasia, raising the initial hypotheses of mucoepidermoid carcinoma, mammary analogue carcinoma, acinar cell carcinoma or adenocarcinomas with No Other Specification (NOS).

The immunohistochemical analysis was strongly reactive for S100 and mamoglobin (Figure 4), and the combination of morphological and an immunohistochemical finding was compatible with the diagnosis of mammary analogue secretory carcinoma in the parotid gland. Due to the presence of extensive perineural invasion and compromised surgical margins, the patient was...
Liandra R de S Barbosa, et al., Clinics in Surgery - Plastic Surgery

referred for adjuvant radiotherapy and is in good overall condition with no evidence of disease after one year of treatment.

Discussion

The MASC was first described by Skálova in 2010 in a clinical-pathological study of 16 salivary gland tumors that had characteristics that resembled the histomorphology found in secretory carcinomas of the breast. Since then, in recent years, more than 90 cases of MASC have been described, based mainly on retrospective studies, which may indicate that the tumor is not as rare as previously thought, but rather a tumor that has been scarcely studied (Table 1). Most published studies have a description of the immunohistochemical and genetic characteristics as their main focus, and the knowledge about clinical presentation and tumor progression is still limited. In most of the reports used in this research, as in the case presented by our patient, clinical presentation at the time of diagnosis is summarized as the appearance of a nodule or swelling in the region of the affected salivary gland, usually the parotid, from a few months to little more than one year of evolution and no association with other symptoms [3,5,6,7,10,11]. However, other symptoms were also observed, such as weight loss [11], pain [8], skin infiltration [8], cervical lymphadenopathy [7,8] and ulceration of the affected region [4,8]. The MASC is considered a low-grade carcinoma with a low course and favorable prognosis [4,9] however, both local involvement and lymph node metastasis may occur [5,7].

Histologically, its resemblance to the secretory carcinoma of the breast is striking. In most cases, MASC has microcystic or solid tubular structures, cells with vacuolated cytoplasm, with abundant eosinophilic secretory material and oval to round vesicular nuclei [3,7,12] however, it is possible to observe a less common presentation, with the tumor dominated by large cysts with multilayer coating, exhibiting tubular, follicular or papillary architecture, with occasional occurrence of solid areas. The neoplastic gland secretions are strongly positive for Periodic Acid-Schiff (PAS) staining [12]. Our patient had, at the histopathological analysis of the surgical specimen obtained at the partial parotidectomy, neoplasia of atypical epithelial cells, with

Table 1: Characteristics of patients with MASC diagnostic in nine case series.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Number of cases</th>
<th>Male/ Female</th>
<th>Age</th>
<th>Site</th>
<th>Lymph node involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>[2]</td>
<td>2010</td>
<td>16</td>
<td>9/7</td>
<td>21-75</td>
<td>Parotid (n=13)</td>
<td>No Information</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Minor salivary gland (n=1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lip (n=1)</td>
<td></td>
</tr>
<tr>
<td>[5]</td>
<td>2012</td>
<td>1</td>
<td>0/1</td>
<td>34</td>
<td>Parotid (n=1)</td>
<td>No</td>
</tr>
<tr>
<td>[3]</td>
<td>2014</td>
<td>1</td>
<td>0/1</td>
<td>58</td>
<td>Parotid (n=1)</td>
<td>No</td>
</tr>
<tr>
<td>[7]</td>
<td>2014</td>
<td>4</td>
<td>1/3</td>
<td>28-83</td>
<td>Parotid (n=1)</td>
<td>Yes (n=1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Minor salivary gland (n=2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Submandibular gland (n=1)</td>
<td></td>
</tr>
<tr>
<td>[4]</td>
<td>2014</td>
<td>1</td>
<td>0/1</td>
<td>41</td>
<td>Palate (n=1)</td>
<td>Sim</td>
</tr>
<tr>
<td>[8]</td>
<td>2014</td>
<td>7</td>
<td>5/2</td>
<td>17-73</td>
<td>Palate (n=6)</td>
<td>Sim (n=3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Parotid (n=2)</td>
<td></td>
</tr>
<tr>
<td>[11]</td>
<td>2015</td>
<td>2</td>
<td>2/0</td>
<td>42,60</td>
<td>Parotid (n=2)</td>
<td>N/I</td>
</tr>
<tr>
<td>[9]</td>
<td>2015</td>
<td>1</td>
<td>1/0</td>
<td>66</td>
<td>Parotid (n=1)</td>
<td>No</td>
</tr>
<tr>
<td>[6]</td>
<td>2016</td>
<td>3</td>
<td>1/2</td>
<td>09-45</td>
<td>Parotid (n=3)</td>
<td>No</td>
</tr>
</tbody>
</table>

N/I: No Information
large, vesicular nuclei, generally with evident nucleoli, in addition
to cells with acinar arrangement, focally of microcystic, ductal and
occasionally follicular aspect, having also a solid arrangement and
papillary outlines. There was also the presence of extensive perineural
invasion and compromised surgical margin. As with the secretory
carcinoma of the breast, MASC is positive for proteins such as
mammaglobin, vimentin and S-100, and is non-immunoreactive
to estrogen receptor, progesterone receptor and negative for Her2
(triple negative); furthermore, it shares a specific gene mutation,
the translocation t (12;15) (p13;q25) that leads to the formation
of the ETV6-NTRK3 oncogene [4,9,12] identical to that found in
the secretory carcinoma of the breast. The gene resulting from the
ETV6-NTRK3 fusion encodes a chimeric tyrosine kinase that has
the potential to undergo a malignant transformation and plays a
major role in oncogenesis [8,14]. This genetic characteristic has also
been found in congenital fibrosarcoma, mesoblastic nephroma, and
acute myeloid leukemia [7]. Our patient showed strongly reactive
immunohistochemistry for S100, AE1AE3 and mammaglobin and
was negative for calponin, GCDPF-15, CK14 and DOG1.

Therefore, we realized that the MASC has specific histological
and immunohistochemical characteristics, which together would be
sufficient to attain its diagnosis. However, it also has characteristics
that overlap with those of other types of salivary gland cancers [2,12],
which may hinder the diagnosis. Mucoepidermoid carcinoma, acinar
cell carcinoma and adenocarcinoma with NOS are the major tumors
that can by mistakenly diagnosed as MASC [6].

Conclusion

Although considered to be a rare condition, studies related to
mammary analogue secretory carcinoma in salivary glands show
that an under diagnosis of this entity has been occurring, due to its
similarities to other types of cancer considered to be more common,
and that it is always important to consider it in the differential
diagnosis of mucoepidermoid carcinomas, adenocarcinomas with
NOS and acinar cell carcinomas. Moreover, studies concerning the
treatment and follow-up of this recent pathology are required.

References

1. El-Naggar AK, Chang JK, Grandis JR, Takata T, Slootweg PJ. WHO
Mammary analogue secretory carcinoma of salivary glands, containing the
ETV6–NTRK3 fusion gene: a hitherto undescribed salivary gland tumor
Mammary analogue secretory carcinoma: Update on a New Diagnosis
Mammary analog secretory carcinoma of salivary gland with high-grade
histology arising in hard palate, report of a case and review of literature.
of mammary analogue secretory carcinoma of accessory parotid gland:
another diagnostic dilemma in matrix-containing tumors of the salivary
analogue secretory carcinoma of parotid: Is preoperative cytological
7. Serrano-Arévalo ML, Mosqueda-Taylor A, Domínguez-Malagón H,
Michal M. Mammary Analogue Secretory Carcinoma (MASC) of salivary
gland in four Mexican patients. Medicina Oral, Patología Oral y Cirugía
E, et al. Mammary analog secretory carcinoma of parotid gland: A case
Cytological Features of Mammary Analogue Secretory Carcinoma of the
Parotid Gland in a 15-Year-Old Girl: A Case Report with Review of the
11. Salat H, Muntaz R, Ikrar M, Din NU. MammaryAnalogueSecretory
Carcinoma of the ParotidGland: A Third World Country Perspective-A
